CAMP4 THERAPEUTICS CORPORATION (CAMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has a cash flow conversion efficiency ratio of -0.355x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.98 Million) by net assets ($30.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CAMP cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
CAMP4 THERAPEUTICS CORPORATION - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CAMP4 THERAPEUTICS CORPORATION Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PennantPark Investment Corporation
NYSE:PNNT
|
0.000x |
|
Mahanagar Telephone Nigam Limited
NSE:MTNL
|
0.004x |
|
Anhui Huaqi Environmental Protection Technology Co. Ltd.
SHE:300929
|
N/A |
|
Huons Co. Ltd
KQ:243070
|
0.028x |
|
Partron Co. Ltd
KQ:091700
|
0.085x |
|
CS Disco LLC
NYSE:LAW
|
-0.094x |
|
Hinduja Global Solutions Limited
NSE:HGS
|
0.011x |
|
Jack In The Box Inc
NASDAQ:JACK
|
-0.036x |
Annual Cash Flow Conversion Efficiency for CAMP4 THERAPEUTICS CORPORATION (1989–2025)
The table below shows the annual cash flow conversion efficiency of CAMP4 THERAPEUTICS CORPORATION from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see how much is CAMP4 THERAPEUTICS CORPORATION worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $47.70 Million | $-29.55 Million | -0.620x | +14.14% |
| 2024-12-31 | $63.14 Million | $-45.56 Million | -0.722x | -302.19% |
| 2023-12-31 | $-123.73 Million | $-44.16 Million | 0.357x | -28.21% |
| 2022-12-31 | $-77.53 Million | $-38.54 Million | 0.497x | +1045.01% |
| 2021-12-31 | $80.18 Million | $-4.22 Million | -0.053x | -118.28% |
| 2020-12-31 | $99.32 Million | $28.59 Million | 0.288x | +243.86% |
| 2019-12-31 | $137.92 Million | $11.54 Million | 0.084x | -63.94% |
| 2018-12-31 | $205.65 Million | $47.74 Million | 0.232x | -30.97% |
| 2017-12-31 | $198.92 Million | $66.89 Million | 0.336x | +113.79% |
| 2016-12-31 | $164.00 Million | $25.80 Million | 0.157x | -37.13% |
| 2015-12-31 | $189.45 Million | $47.40 Million | 0.250x | +32.23% |
| 2014-12-31 | $151.38 Million | $28.64 Million | 0.189x | +10.42% |
| 2013-12-31 | $133.15 Million | $22.82 Million | 0.171x | +21.37% |
| 2012-12-31 | $117.55 Million | $16.60 Million | 0.141x | -71.63% |
| 2011-12-31 | $24.98 Million | $12.43 Million | 0.498x | +922.31% |
| 2010-12-31 | $17.60 Million | $857.00K | 0.049x | -62.19% |
| 2009-12-31 | $19.20 Million | $2.47 Million | 0.129x | -78.29% |
| 2008-12-31 | $23.20 Million | $13.76 Million | 0.593x | +3050.37% |
| 2007-12-31 | $73.42 Million | $-1.48 Million | -0.020x | -118.18% |
| 2006-12-31 | $151.25 Million | $16.72 Million | 0.111x | -13.00% |
| 2005-12-31 | $176.11 Million | $22.38 Million | 0.127x | +60.46% |
| 2004-12-31 | $158.29 Million | $12.54 Million | 0.079x | +1.62% |
| 2003-12-31 | $65.36 Million | $5.09 Million | 0.078x | -16.61% |
| 2002-12-31 | $58.62 Million | $5.48 Million | 0.093x | -71.47% |
| 2001-12-31 | $37.58 Million | $12.31 Million | 0.328x | +32.12% |
| 2000-12-31 | $30.28 Million | $7.51 Million | 0.248x | +2277.78% |
| 1999-12-31 | $28.09 Million | $293.00K | 0.010x | -96.49% |
| 1998-12-31 | $20.20 Million | $6.00 Million | 0.297x | +114.85% |
| 1997-12-31 | $21.70 Million | $3.00 Million | 0.138x | +162.86% |
| 1996-12-31 | $24.10 Million | $-5.30 Million | -0.220x | -148.89% |
| 1995-12-31 | $22.90 Million | $10.30 Million | 0.450x | +97.11% |
| 1994-12-31 | $14.90 Million | $3.40 Million | 0.228x | +1027.96% |
| 1993-12-31 | $12.20 Million | $-300.00K | -0.025x | -107.80% |
| 1992-12-31 | $7.30 Million | $2.30 Million | 0.315x | -22.28% |
| 1991-12-31 | $3.70 Million | $1.50 Million | 0.405x | +170.27% |
| 1990-12-31 | $2.00 Million | $300.00K | 0.150x | +50.00% |
| 1989-12-31 | $2.00 Million | $200.00K | 0.100x | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more